NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
10/24/2023
Back to search
Official data from USPTO
DRUG CENTRAL
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
30
Latest update
10/24/2023
Trademark type
Combined
Nice classes
42
Filing date
12/30/2021
Registration date
10/24/2023
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
10/24/2023
Last transaction
10/24/2023
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
01/01/2019
First use in commerce
01/01/2019
Drawing code
3
Owner type
03
Owner location
San Juan, PR, US
Examiner
GILBERT, REBECCA
Law office
L30
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the term DRUG in aqua blue on top of the term CENTRAL in aqua blue. To the left, there are images of the outline of a pill, the outline of a medicine bottle and three horizontal lines, all in red. The gray in the mark is background area which is not a part of the mark.
Holders and representatives
Holders
Central Drug Dorado Corp.
Representatives
Cristina Arenas FERRAIUOLI LLC
Technical classification
Nice Classes
Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 42
Providing a website featuring non-downloadable software for drug distribution logistics and operations management
Publications
History of USPTO decisions and trademark events.
30 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
10/24/2023
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
09/20/2023
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
09/20/2023
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
09/19/2023
SUPC
STATEMENT OF USE PROCESSING COMPLETE
09/19/2023
EX1G
SOU EXTENSION 1 GRANTED
09/19/2023
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
09/19/2023
IUAF
USE AMENDMENT FILED
09/12/2023
NREV
NOTICE OF REVIVAL - E-MAILED
09/12/2023
EISU
TEAS STATEMENT OF USE RECEIVED
09/12/2023
TPEX
SOU EXTENSION RECEIVED WITH TEAS PETITION
09/12/2023
PETG
PETITION TO REVIVE-GRANTED
09/12/2023
PROA
TEAS PETITION TO REVIVE RECEIVED
09/12/2023
MAB6
ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
08/07/2023
ABN6
ABANDONMENT - NO USE STATEMENT FILED
08/07/2023
EXT1
SOU EXTENSION 1 FILED
07/03/2023
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
01/03/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
11/08/2022
PUBO
PUBLISHED FOR OPPOSITION
11/08/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
10/19/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
10/06/2022
XAEC
EXAMINER'S AMENDMENT ENTERED
10/06/2022
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
10/06/2022
GNEA
EXAMINERS AMENDMENT E-MAILED
10/06/2022
CNEA
EXAMINERS AMENDMENT -WRITTEN
10/06/2022
DOCK
ASSIGNED TO EXAMINER
10/04/2022
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
01/06/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
01/05/2022
NWAP
NEW APPLICATION ENTERED
01/03/2022
Continuous trademark protection
Get notified about every new filing that threatens DRUG CENTRAL or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.